Although these therapies enhance tumor therapeutic efficacy, the majority induce more adverse effects than treatment with anti‐PD1 (aPD1) plus anti‐CTLA‐4 (aCTLA‐4) antibodies. This evidence concerns the gene CTLA4 and neoplasm.